Ronald Antonio Ferguson

US Patent:

20190315708, Oct 17, 2019

Filed:

Dec 18, 2017

Appl. No.:

16/471679

Inventors:

Jianming BAO - Shanghai, CN
Ronald FERGUSON - Rahway NJ, US
Xiaolei GAO - Bridgewater NJ, US
Scott HARRISON - West Point PA, US
Sandra L. KNOWLES - Kenilworth NJ, US
Michael Man-chu LO - Kenilworth NJ, US
Jeffrey W. SCHUBERT - West Point PA, US
- Rahway NJ, US
- Shanghai, CN

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07D 401/04
C07D 401/14
C07D 417/14
C07D 513/04
C07D 405/14
C07D 413/14
C07D 498/08
C07D 491/107

Abstract:

The present invention is directed to heteroarylpiperidine ether compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

US Patent:

20180319804, Nov 8, 2018

Filed:

Jul 11, 2018

Appl. No.:

16/032715

Inventors:

- Rahway NJ, US
Xianhai Huang - Warren NJ, US
Ronald D. Ferguson - Scotch Plains NJ, US
Wei Zhou - Scotch Plains NJ, US
Christopher W. Boyce - Flemington NJ, US
Phieng Siliphaivanh - Newton MA, US
David J. Witter - Norfolk MA, US
Milana M. Maletic - Summit NJ, US
Joseph A. Kozlowski - Princeton NJ, US
Kevin J. Wilson - Boston MA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07D 487/04
C07D 519/00
C07D 471/04
C07D 471/14

Abstract:

Disclosed are the ERK inhibitors of formula (1):and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (I).

US Patent:

20180028509, Feb 1, 2018

Filed:

Oct 5, 2017

Appl. No.:

15/725407

Inventors:

- Rahway NJ, US
Yonglian Zhang - Metuchen NJ, US
Sherman Tim Waddell - Westfield NJ, US
Andrew Stamford - Chatham NJ, US
John S. Wai - Harleysville PA, US
Paul J. Coleman - Harleysville PA, US
John M. Sanders - Collegeville PA, US
Ronald Ferguson - Scotch Plains NJ, US
Thomas H. Graham - Quincy MA, US
Hong Li - Edison NJ, US

Assignee:

MERCK SHARP & DOHME CORP. - Rahway NJ

International Classification:

A61K 31/4375
C07D 519/00
A61K 31/52
A61K 31/513
A61K 31/505
A61K 31/4745
A61K 31/4402
A61K 31/427
A61K 31/635
A61K 31/444
C07D 455/00
C07D 455/04
C07D 471/14
C07D 491/147
A61K 45/06
A61K 31/675
C07D 455/02

Abstract:

The present invention relates to Substituted Quinolizine Derivatives of Formula (I):and pharmaceutically acceptable salts or prodrug thereof, wherein X, Y, R, R, R, R, R, Rand Rare as defined herein. The present invention also relates to compositions comprising at least one Substituted Quinolizine Derivative, and methods of using the Substituted Quinolizine Derivatives for treating or preventing HIV infection in a subject.

US Patent:

20170320882, Nov 9, 2017

Filed:

Jul 21, 2017

Appl. No.:

15/656176

Inventors:

- Rahway NJ, US
Xianhai Huang - Warren NJ, US
Ronald D. Ferguson - Scotch Plains NJ, US
Wei Zhou - Scotch Plains NJ, US
Christopher W. Boyce - Flemington NJ, US
Phieng Siliphaivanh - Newton MA, US
David J. Witter - Norfolk MA, US
Milana M. Maletic - Summit NJ, US
Joseph A. Kozlowski - Princeton NJ, US
Kevin J. Wilson - Boston MA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07D 487/04
C07D 471/04
C07D 471/14
C07D 519/00

Abstract:

Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (I).

US Patent:

20170275302, Sep 28, 2017

Filed:

Oct 9, 2015

Appl. No.:

15/505266

Inventors:

Alexander PASTERNAK - Kenilworth NJ, US
Barbara PIO - Kenilworth NJ, US
Harry R. CHOBANIAN - Kenilworth NJ, US
Zhi-Cai SHI - Kenilworth NJ, US
Shuzhi DONG - Kenilworth NJ, US
Yan GUO - Kenilworth NJ, US
Shawn P. WALSH - Kenilworth NJ, US
Zhiqiang GUO - Rahway NJ, US
Ronald D. FERGUSON - Rahway NJ, US
Brian CATO - Secaucus NJ, US
- Rahway NJ, US

International Classification:

C07D 519/00
A61K 31/4985
C07D 471/10
A61K 31/435
C07D 498/10
A61K 31/519
A61K 31/437
A61K 31/4365
A61K 31/4375
A61K 31/4355
A61K 45/06
A61K 31/5025

Abstract:

The present invention provides compounds of Formula (I) and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

US Patent:

20160257670, Sep 8, 2016

Filed:

Oct 27, 2014

Appl. No.:

15/032174

Inventors:

- Rahway NJ, US
Haifeng Tang - Metuchen NJ, US
Jessica Frie - Perkasie PA, US
Ronald Dale Ferguson - Scotch Plains NJ, US
Zhiqiang Guo - Morganville NJ, US
Zhi-Cai Shi - Monmouth Junction NJ, US
Brian Cato - Secaucus NJ, US
Qinghong Fu - Plainsboro NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07D 405/06
A61K 31/427
C07D 471/04
C07D 513/04
C07D 417/14
A61K 45/06
A61K 31/4525
A61K 31/4545
C07D 405/14
A61K 31/433
A61K 31/4439
A61K 31/454
C07D 413/14

Abstract:

The present invention provides compounds of Formula Iand the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

US Patent:

20160228419, Aug 11, 2016

Filed:

Sep 26, 2014

Appl. No.:

15/025038

Inventors:

- Rahway NJ, US
Yonglian Zhang - Metuchen NJ, US
Sherman Tim Waddell - Westfield NJ, US
Andrew Stamford - Chatham NJ, US
John S. Wai - Harleysville PA, US
Paul J. Coleman - Harleysville PA, US
John M. Sanders - Collegeville PA, US
Ronald Ferguson - Scotch Plains NJ, US

Assignee:

MERCK SHARP & DOHME CORP. - Rahway NJ

International Classification:

A61K 31/4375
C07D 455/02
C07D 519/00
C07D 471/14
A61K 31/444
C07D 455/04
C07D 455/00
A61K 45/06
C07D 491/147

Abstract:

The present invention relates to Substituted Quinolizine Derivatives of Formula (I): and pharmaceutically acceptable salts or prodrug thereof, wherein X, Y, R, R, R, R, R, Rand Rare as defined herein. The present invention also relates to compositions comprising at least one Substituted Quinolizine Derivative, and methods of using the Substituted Quinolizine Derivatives for treating or preventing HIV infection in a subject.

US Patent:

20160068532, Mar 10, 2016

Filed:

Apr 25, 2014

Appl. No.:

14/787280

Inventors:

Jongwon LIM - , US
Xianhai HUANG - , US
Ronald D. FERGUSON - Rahway NJ, US
Wei ZHOU - Rahway NJ, US
Christopher W. BOYCE - Rahway NJ, US
Phieng SILIPHAIVANH - Boston MA, US
David J. WITTER - Boston MA, US
Milana M. MALETIC - Rahway NJ, US
Joseph A. KOZLOWSKI - Rahway NJ, US
Kevin J. WILSON - Boston MA, US
- Rahway NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07D 487/04
C07D 471/14
C07D 471/04

Abstract:

Disclosed are the ERK inhibitors of formula (I) and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (I). This invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of formula (I) and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of formula (I) and an effective amount of at least one other pharmaceutically active ingredient (such as, for example, a chemotherapeutic agent), and a pharmaceutically acceptable carrier. This invention also provides a method of inhibiting ERK (i.e., inhibiting the activity of ERK2) in a patient in need of such treatment comprising administering to said patient an effective amount of at least one compound of formula (I).